Pet scan to see how lung cancer responds to immunotherapy before surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a special PET scan can predict how well your tumor responds to an immunotherapy drug given before surgery. Participation may help doctors tailor your treatment and improve outcomes for early-stage lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years or older.
- You have been diagnosed with adenocarcinoma or squamous cell lung cancer, and the tumor is between 1 and 5 centimeters (about 0.4 to 2 inches).
- You are scheduled for surgery to remove the cancer with the goal of cure.
- You have adequate organ function (blood counts, kidney, and liver) as determined by routine tests.
- You must not have certain rare subtypes of lung cancer or a known druggable gene change that can be treated with a targeted drug.
- You must not have an active infection, autoimmune disease, prior organ transplant, or a blood disorder that requires treatment that could affect your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses special PET scans to see how well your immune cells respond to immunotherapy given before surgery for non-small cell lung cancer. The goal is to learn which patients benefit most from this treatment approach.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This trial tests a combination of three treatments given before surgery for lung cancer: targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib). The goal is to shrink the tumor and improve the chance of successful surgery.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.